Table 3. Differences in Glycemic Variability Indices according to the Regimen of Antidiabetic Agents.
| Variable | SD, mmol/L | MAG, mmol/L/hr |
|---|---|---|
| Drug naïve (n=18) | 1.775 (1.389-2.023)a | 0.920 (0.674-1.119)a |
| Mono-therapy (n=50) | ||
| MET (n=39) | 1.624 (1.452-2.328)a | 0.863 (0.669-1.277)a |
| SU (n=11) | 2.260 (1.925-3.263) | 1.122 (0.955-1.833) |
| Dual-therapy (n=122) | ||
| MET+DPP4i (n=25) | 1.658 (1.352-2.267)a | 0.824 (0.693-1.168)a |
| MET+SU (n=85) | 2.547 (2.140-3.158) | 1.301 (1.098-1.660) |
| Triple-therapy (n=19) | ||
| MET+SU+AGI (n=9) | 1.621 (1.157-2.886)a | 0.726 (0.525-1.368)a |
| MET+SU+TZD (n=9) | 2.168 (2.037-2.449) | 1.307 (1.095-1.588) |
Values are expressed as median (interquartile range).
SD, standard deviation; MAG, mean absolute glucose change; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; TZD, thiazolidinedione.
aP<0.05 when compared with MET+SU by Mann-Whitney test.